Skip to content

Vaginal Compared With Intramuscular Progesterone for Prevention of Preterm Birth in High Risk Pregnant Women

A Multicenter, Randomized, Open-label, Investigator Initiated Trial of Vaginal Compared With Intramuscular Progesterone for Prevention of Preterm Birth in High Risk Pregnant Women

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02304237
Enrollment
360
Registered
2014-12-01
Start date
2014-12-31
Completion date
2016-12-31
Last updated
2014-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Premature Birth

Keywords

Premature Birth, progesterone

Brief summary

This study is for compare the efficacy of two different regimens(vaginal vs intramuscular) of progesterone therapy in prevention of preterm birth in high risk pregnant women.

Detailed description

The objectives of this study is 1) To compare the efficacy of two different regimens of progesterone therapy in preventing preterm birth less than 37 weeks of gestation. 2) To compare the cost-benefit, adverse effects and patient preference of two different regimens of progesterone therapy. Design: Multi-center, randomized, open-label trial

Interventions

DRUGVaginal progesterone

micronized progesterone 200mg/day till 36 weeks 6 days of gestation or premature rupture of membranes

hydroxyprogesterone caproate 250mg/ml/week till 36 weeks 6 days of gestation or premature rupture of membranes

Sponsors

Samsung Medical Center
CollaboratorOTHER
Han Wha Pharma Co., Ltd.
CollaboratorINDUSTRY
Ministry of Health & Welfare, Korea
CollaboratorOTHER_GOV
Ewha Womans University Mokdong Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
20 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* With a history of prior spontaneous preterm birth or short cervix length * Spontaneous preterm birth: preterm birth \<37 weeks of gestation due to spontaneous preterm labor or preterm premature rupture of membranes (PPROM) * Short Cervix length : cervix length \<25 mm as measured by transvaginal ultrasound at 16-24 weeks of gestation

Exclusion criteria

* Multiple gestations * Major congenital anomalies * Elective prophylactic cervical cerclage \<16 weeks of gestation during current pregnancy * Previous intentional preterm birth due to maternal or fetal indications, such as preeclampsia and fetal growth restriction * Diabetes, hypertension, other severe medical diseases

Design outcomes

Primary

MeasureTime frame
Preterm Birth Rate before 37 weeks of gestationfrom study enrollment to maximum 37 weeks of gestation

Secondary

MeasureTime frame
Preterm Birth Rate before 34 weeks of gestationfrom study enrollment to maximum 34 weeks of gestation
Preterm Birth Rate before 28 weeks of gestationfrom study enrollment to maximum 28 weeks of gestation
Result of birth(rate of death, weight, cause of hospitalization to NICU)from study enrollment to maximum 37 weeks of gestation
Any complications occurred to newborn and motherfrom study enrollment to maximum 37 weeks of gestation

Contacts

Primary ContactYoung Ju Kim
kkyj@ewha.ac.kr822-2650-5500
Backup ContactSUK-JOO CHOI
drmaxmix.choi@samsung.com822-3410-3546

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 18, 2026